We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Lawmakers Consider Adding Four Device Bills to MDUFA Reauthorization

Lawmakers Consider Adding Four Device Bills to MDUFA Reauthorization

May 2, 2017

A House subcommittee held a hearing Tuesday on the MDUFA reauthorization and four additional device-related measures it is considering attaching to the user fee legislation.

The draft MDUFA bill would extend the existing MDUFA programs to 2022, and include new fees for de novo reviews. Anticipated fees to be collected would increase from $130.2 million for the current fiscal year to $183.3 million in fiscal 2018 and to $213.7 million for fiscal 2022.

One bill the lawmakers may combine with the MDUFA package aims to make hearing aids more accessible over the counter by doing away with the need for an examination or signed waiver in order for a patient to buy or receive the device.

The bill would:

  • Make hearing aids, intended to be used by adults to compensate for mild to moderate hearing impairment, available over the counter;
  • Remove requirements that consumers obtain a medical evaluation or sign a waiver of that examination in order to obtain an OTC hearing aid;
  • Require the FDA to issue regulations with safety and labeling requirements for this new category of OTC hearing aids;
  • Maintain existing safety, labeling, and manufacturing protections; and
  • Require the FDA to update its draft guidance on personal sound amplification products — consumer electronics products that may use similar technology to hearing aids, but are intended for use by individuals with normal hearing.

View today's stories

Devices Regulatory Affairs

    Upcoming Events

    • 30Nov

      Medical Device Cybersecurity: Latest Regulatory Developments

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 07Dec

      Proactive Supplier Management Using Quality Agreements

    • 13Dec

      FDA Inspection Overhaul: How Things Have Changed in 2023

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Lilly’s Claims of Mounjaro Trademark Infringement Get ITC Investigation

    • Positive Findings Generated by Element Science’s Jewel Wearable Cardiac Defibrillator

    • Biden Offers Drug Supply Chain Fixes, but Think Tank Says Government Isn’t Doing Enough

    • FDA Gives Green Light to Medtronic’s Symplicity Renal Denervation System

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing